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ABSTRACT
Background: Caesarean operation remains the most common abdominal surgery 
in women and has immense benefits to both mother and baby when employed. 
Haemorrhage, however, remains the greatest challenge associated with its outcome. 
Objective: To compare the effectiveness of pre-operative sub-lingual misoprostol with 
intravenous oxytocin administered after delivery of the neonate in minimising blood 
loss at Caesarean operation
Design: A prospective study.
Results: The mean blood loss was significantly lower in misoprostol group compared 
to oxytocin group (517.32mls versus 621.22mls;  p = 0.005). The drop in haematocrit was 
significantly lower in misoprostol group than the oxytocin group, (400μg-misoprostol 
versus oxytocin: 1.88 versus 3.04; p=0.0001). Side effects of chills, shivering and pyrexia 
were noted more with the use of misoprostol.
Conclusion: Pre-operative sub-lingual misoprostol is more effective than intravenous 
infusion of oxytocin in reducing blood loss at Caesarean section operation. However, 
occurrence of transient side effects of chills, shivering and pyrexia were noted more 
with use of misoprostol.
INTRODUCTION
Caesarean operation remains the most commonly 
performed major abdominal operation in women in 
both affluent and low-income countries and the rates 
vary considerably between and within countries (1, 2). 
Global estimates have indicated a Caesarean delivery 
rate of 15% worldwide, ranging from 3.5% in Africa to 
29.2% in Latin America and the Caribbean(3). These 
rates have continued to increase both in affluent and 
low-resource countries, including Nigeria (4). In the 
United States it has increased from about 21% in 1996 
to 32% in 2007 (5). In Nigeria rates from 20.8 to 34.6% 
have been reported in tertiary institutions and private 
hospitals (6). Reasons for these increases include 
improved global awareness on benefits and safety of 
the procedure, increasing foetal survival compared 
to difficult vaginal deliveries and introduction of 
electronic foetal monitors (7). In addition diminishing 
proficiency in the arts of operative vaginal deliveries 
coupled with difficult referral system have made 
Caesarean delivery a preferred alternative even 
September 2012 East african MEdical Journal    295
in the less endowed settings of the less developed 
countries (8). 
 Many secondary healthcare institutions are 
located in rural and semi-urban communities in 
Nigeria and they undertake surgical procedures that 
include Caesarean deliveries to relieve parturient 
mothers in difficult labour or intervene to salvage 
a compromised foetus (4,9). Challenges against 
successful outcome are largely haemorrhage and 
sepsis, and these two have been largely expressed 
as major contributors to both Caesarean maternal 
morbidity and mortality (10). Challenge of sepsis 
is daily being relieved by novel provisions of 
antibacterial agents of increasing potency and 
coverage.  However, challenge of haemorrhage has 
no alternative other than provision of blood. In rural 
and semi-urban Nigeria the blood banking services 
are far from being optimal sequel to malnutrition 
and blood borne diseases that make blood donation 
scarce (10). Alternative to overcoming haemorrhagic 
challenge, therefore, will be to employ strategies that 
will minimise blood loss at surgery. To achieve these 
oxytocic drugs, oxytocin (syntocinon or pitocin) and 
methyl-ergometrine (methergine), are conventionally 
employed parenterally during Caesarean operations. 
These oxytocics are available in Nigeria in many 
generic types of doubtful potencies. Syntocinon and 
methergine are rare brands and when available their 
potencies may not be optimal from poor storage 
practices and the humid hot environment. The lack of 
these effective oxytocics further compounds the ability 
of the surgeon to combat haemorrhagic challenge in 
poor-resource settings.
 Misoprostol is an analogue of prostaglandin 
(15-deoxy-16-hydroxy-16-methyl-PGE1) and an 
H2-receptor agonist, marketed by Pfizer as cytotec 
and originally labeled for treating gastric ulcer and 
patients on non-steroidal anti-inflammatory drugs 
(NSAID) (11). It is prepared in tablets form and can 
be administered orally, sub-lingually, vaginally and 
rectally. It is used in obstetrics and gynaecology to 
induce or augment labour, or perform mid-trimester 
abortions. It is also employed to prevent and treat 
post-partum haemorrhage (12). Between 2005 and 
2008 it became licensed for obstetric and gynaecologic 
uses by World Health Organisation (WHO) and in 
more than 50 countries, including Nigeria (13). It 
has been found to be a good alternative to oxytocin 
or methylergometrine in treating or preventing post-
partum haemorrhage (12).
 Misoprostol when administered rectally or 
vaginally will take between 30 and 40 minutes to 
peak, will peak at 15 to 20 minutes when administered 
sub-lingual and five to ten minutes when given 
as oral solution (11, 12). Several studies that have 
compared misoprostol and oxytocin in our review 
showed that misoprostol was administered either 
rectally or vaginally and after delivery of the baby. 
A few that employed misoprostol sub-lingually also 
administered the drug after delivery of the baby. In 
these studies one would infer that optimal effect of 
misoprostol was not being employed at the time 
appropriate for desired result. Misoprostol when 
given sub-lingually at a time when the patient is 
being shifted from the ward to the operating room 
for surgery, would be peaking just before delivery or 
immediately after delivery of the baby. 
 The aim of this study was to compare the 
effectiveness of pre-operative sub-lingual misoprostol 
with intravenous oxytocin administered after delivery 
of the neonate in minimising blood loss at Caesarean 
operation.  
MATERIALS AND METHODS
This prospective study was conducted between 
April 2009 and March 2011 at the Obstetrics and 
Gynaecology unit of Olabisi Onabanjo University 
Teaching Hospital, Sagamu, Nigeria. Sagamu is a 
semi-urban town 50 miles north of Lagos, Nigeria. The 
study was approved by the Hospital Ethics Committee 
in accordance with local research requirements 
in November 2008. Method and procedures were 
explained to prospective participating women before 
signing informed consent form.
 One hundred women in labour or on admission 
for elective or emergency Caesarean delivery that 
have consented to be part of the study were randomly 
assigned to two groups. In one group each woman 
received two tablets of 400μgms tablet of misoprostol 
and in the other group each woman received 20 
international units of oxytocin injection intravenously 
after the delivery of the neonate. In the misoprostol 
group the tablets were administered sub-lingually by 
the nurse while the woman was being shifted from 
labour ward to the operating room.
The population size determination was derived using 
sample size formula to compare two mean 
values; n = 
2(Z1–α/2 + Z1– β)2σ2
ρ2
Where n is the minimum sample size required, Z is 
the standard normal deviate, α is the type 1 error, β 
is the type 2 error, σ is the standard deviation, and d 
is the standardised difference.
If α = 0.05, Z1-α/2 = 1.96, β = 0.20, power = 80%, 
Z1-β =0.84, σ =215, and d=150; Therefore n = 32.049 
per group.
 Included in this study were women whose 
pregnancies were 34 weeks and above, primigravidae 
or nulliparae and multiparae with not more than 
five parous experiences. Excluded were women 
with previous Caesarean operation, ante-partum 
haemorrhage or related complications and history 
of ante-partum haemorrhage in previous or current 
pregnancy. Also excluded were women with previous 
296 East african MEdical Journal September 2012 
history of dilatation and curettage, deranged 
coagulation profile or platelet counts of less than 
100 × 10–9 and women with history of allergy to 
prostaglandin or prostaglandin analogues. Women 
with hypertensive disorders associated with elevated 
liver enzymes, low platelets and elevated leucocytes 
dehydrogenase enzyme (LDH) were also excluded 
from this study. 
 The chief reason for Caesarean operation in 
woman with multiple complications was considered 
as indication for Caesarean delivery in this study.
The surgeries were performed under spinal analgesia 
and the surgical technique adopted was modification 
of Misgav-Ladach and traditional Pfannestiel 
procedures (1, 14, 15). During the course of surgery 
minor bleeders were cauterised with diathermy and 
major bleeders were ligated with sutures. All the 
surgeries were performed by consultant staff and 
post-fellowship senior registrars of the study team.
Blood loss at surgery was estimated by the gravimetric 
method; meticulous suctioning of blood into suction 
bottle from bleeding pool at operation sites and 
mopping with gauze towels. The liquor amni was 
also meticulously collected by suction into separate 
bottle. Cotton towels and gauzes were weighed as 
soon as discarded off operation site and operating 
drapes were weighed at the end of surgery. The 
known dry weights of towels, gauzes and drapes were 
subtracted from their wet weights and the difference 
in grammes equated to milliliter of blood, and this 
was added to blood volume in the suction bottle to 
estimate the total loss (16).
 The primary maternal outcome included blood 
loss at surgery, blood transfusion, length of surgery, 
needs for additional oxytocics, admission into 
intensive care unit or maternal death. Secondary 
maternal outcome included change in post-operative 
haematocrit, anaemia, post-operative pain and use 
of analgesia, fever, and wound infection.    
 Primary foetal outcome included Apgar scores 
at one and five minutes, admission into neonatal 
intensive care unit and perinatal death. Secondary 
foetal outcome included encephalopathy, necrotising 
entero-colitis and perinatal or neonatal death.
 Data were analysed using SPSS version 15.0. 
Statistical analysis was performed using the Chi-
square test for categorical variables and the two-tailed 
t-test for continuous variables. One-sample t test was 
used in finding the weighted mean difference (WMD) 
of mean blood loss and length of surgery. One-way 
analysis of variance was used to evaluate the difference 
in the means (MD) of multiple variables. The results 
are presented as mean, standard deviation and range, 
or as numbers and percentages, and p-value < 0.05 
was considered statistically significant.
RESULTS
During the study period a total of one hundred 
pregnant or parturient women consented for the study, 
a group of fifty had 400μgms tablets of misoprostol 
and the other group of fifty had 20 international units 
of oxytocin administered intravenously after delivery 
of the neonate.
 Table 1 shows the indications for Caesarean 
deliveries; foetal distress 33(33.0%) was the leading 
reason for Caesarean deliveries in both study groups, 
next to it was dystocic labour 23(23.0%) and then 
pre-eclampsia and other hypertensive disorders of 
pregnancy 20(20.0%).The least reason for Caesarean 
delivery in the study was pregnancies considered as 
precious, two (2.0%).
 Table 2 demonstrates the descriptive statistics of 
data in both study groups. The ages of the women 
ranged from 18 to 40 years and the mean age was 
29.30 ±5.21 years. The mean parity was 1.99 ±1.51, 
the range being from zero and four. At delivery the 
gestational ages of the pregnancies ranged from 34 
and 41 weeks and the mean was 38.08 ±1.75 weeks. 
The means Apgar scores of the babies at first and five 
minutes were 7.60 ±1.11 and 9.27 ±0.79 respectively. 
The blood loss at surgery ranged from 285mls and 
1080mls and the mean was 555.32 ±151.34mls. The 
duration of surgery ranged from 30 and 95minutes 
and the mean was 47.70 ±14.31 minutes.  Seventy two 
cases (72.0%) were emergency Caesarean deliveries 
and 28 (28.0%) were elective Caesarean operations.
 Table 3 demonstrates comparison of means of 
the primary outcome in both study groups. The table 
demonstrates that the differences in the means of 
length of surgery, length of hospitalisation and Apgar 
scores at five minutes between the study groups were 
not statistically significant. However differences in 
the means of blood loss, intra-operative requirements 
of oxytocics and pre-operative and post-operative 
haematocrit values were statistically significant.
Table 4 is the cross tabulation of occurrences of known 
side effects of misoprostol in the study groups.
 In this study there was no maternal or perinatal 
mortality. There was also no observation of wound 
sepsis.
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Table 1
Indications for Caesarean deliveries






Severe Pregnancy induced hypertension/
Hypertensive disorders in pregnancy
7 13 20 20.0
Uncontrolled Diabetes Mellitus/
Gestational Diabetes Mellitus
1 0 1 1.0
Precious baby (Bad Obstetric history/
Pregnancy after infertility treatment)
1 1 2 2.0
Foetal Distress 18 15 33 33.0
Abnormal lie (Transverse lie/oblique 
lie)
2 1 3 3.0
Malpresentation (Face/brow) 3 2 5 5.0
Dystocia (Foeto-pelvic disproportion/
occipito-posterior/transverse arrest)
14 9 23 23.0
Foetal Macrosomia 1 2 3 3.0
Breech 2 4 6 6.0
Prolonged pregnancy 1 3 4 4.0
Total 50 50 100 100.0
Table 2
Descriptive statistics of the study groups
Description Group 95% CI
















































































































































































































































































































Comparison of means of intravenous oxytocin versus sub-lingual misoprostol
Variable Diff of 
mean









Age of women 28.72 29.88 -1.16 1.06 .525 -3.69 1.37
Parity of women 1.96 2.02 -.06 .30 .979 -.79 .67
Gestational age at 
delivery
38.04 38.12 -.08 .35 .972 .91 .75
Blood loss  a t 
Surgery














3.04 1.88 1.160 243 .000 .58 1.74
Length of surgery 46.60 48.80 -2.20 2.88 .948 -9.04 4.64
Length of 
hospitalisation
5.28 5.42 -1.40 .184 .728 -58 .30
Apgar score at 5 
minutes
9.28 9.22 .02 .164 .815 -.41 .37
Mean values of 
study groups
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Table 4
Cross tabulation of Frequency of known misoprostol side effects in the study groups







Severe abdominal pain 2(4%) 5(10%) .073
Pyrexia 3(6%) 8(16%) .108
Chills 2(4%) 6(12%) .135
DISCUSSION
The mean length of surgery in this study of 47.70 
±14.31 minutes, and perhaps in our practice, is 
significantly longer than 40 minutes as found by 
Hofmayer and colleagues (1), (WMD= 7.70 95% CI 
4.86 – 10.54, p < 0.0001). Modification of Misgav 
Ladach-Pfannestiel technique as employed in this 
study has the merits of being quicker to perform than 
the traditional Pfannestiel. The patients also suffer 
less post-operative pain and recovery of physiologic 
function is faster (15). Probable explanation for this 
difference might be less sophistication in our area of 
practice compared to studies considered in the meta-
analysis by Hofmayer and his team. This mean length 
of surgery may also explain a significantly higher 
mean blood loss, 555.32 ±151.34mls (WMD= 55.32, 
95% CI 25.29 – 85.35, p<0.0001). However as much as 
1000mls of blood is permissible without compromise 
in an otherwise stable woman (17).
 Several studies have demonstrated comparable 
efficacy between misoprostol and oxytocin in 
preventing post-partum haemorrhage (18, 19). In 
majority of these studies misoprostol was employed 
either vaginally or rectally, and was administered 
after delivery of the baby. 
 This study demonstrated that misoprostol when 
administered sub-lingual 15 to 20 minutes before 
the baby is delivered is more effective than oxytocin 
in minimising blood loss at Caesarean operations, 
(oxytocin versus 400μg-misoprostol; MD 131.80, 95% 
CI 65.18 – 198.42, p < 0.0001). 
 Misoprostol will take between 30 to 60 minutes 
to peak when applied vaginally or rectally, 20 to 30 
minutes when administered sub-lingual and when 
ingested as a solution effect will peak in about ten 
minutes (20, 21). It would therefore be inferred that in 
previous studies misoprostol was not being utilised 
at periods of its maximal effect on uterine activities. 
This pharmacokinetics informed our employing 
misprostol sub-lingual and administering it about 
15 to 20 minutes before the anticipated delivery.
 A similar study in Ibadan Nigeria, a comparable 
environment, found no significant difference in blood 
loss between oxytocin and sub-lingual misoprostol 
at Caesarean operation (22). In the study misoprostol 
was also administered sub-lingually but after delivery 
of the baby. In addition, the study considered pre-
operative and four hour post-operative difference 
in haematocrit, a period considered rather short 
for meaningful reflection of haemodynamic change 
following moderate to severe blood loss. In this 
study the difference in haematocrit was between the 
pre-operative and 24-hour post-operative values. 
However, this study compared with findings of 
Vimala and his group in India (23) that demonstrated 
significant reduction in blood loss in sub-lingual 
misoprostol group than the intravenous oxytocin 
group (819mla versus 974mls, p=0.004).
 In this study misoprostol at a dose of 400μg was 
found to be more effective than 20IU of intravenous 
oxytocin at reducing blood loss at Caesarean 
operation. Preoperative sub-lingual misoprostol at 
dose of 400μg was also found to be superior to oxytocin 
in maintaining the uterine tonus after delivery of 
the baby as expressed in the extra μg of methyl-
ergometrine or mililitre of oxytocin administered 
intra-operatively to keep the uterus contracted and 
prevent further blood loss; methyl-ergometrine , 
(oxytocin versus 400μg-misoprostol; MD 180.00, 95% 
CI 90.47 – 269.53, p < 0.0001), oxytocin, (oxytocin 
versus 400μg-misoprostol; MD 589.00, 95% CI 208.88 
– 969.12, p = 0.001).
 Effectiveness of misoprostol, when administered 
sub-lingually and pre-operativly, was further 
expressed in the difference between the pre-operative 
and 24-hour post-operative haematocrit values, 
oxytocin versus misoprostol; MD 1.16, 95% CI .58 
– 1.74, p < 0.0001. Use of misoprostol in treating or 
preventing post-partum haemorrhage is limited by 
side effects such as fever, chills, nausea, headaches, 
abdominal cramps and pain and these occur more 
commonly at doses of 800μg or more (11, 20, 24). 
In this study few side effects of severe abdominal 
pain, fever and chills were observed more in the 
misoprostol group than the oxytocin group (Table 
4). The differences were, however, not statistically 
significant.
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In conclusion, this study has shown that pre-operative 
sub-lingual misoprostol, at a dose of 400μg, is 
more effective in reducing blood loss at Caesarean 
operations than 20IU intravenous oxytocin. It can be 
recommended as alternative, or adjunct, to oxytocin 
in poor-resource settings. 
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